Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.49 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.49 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439196 | 0.93 | ADORA2A (0.54) | ADORA2AADORA2BADORA1PRKAG1PRKAA1 | |
| SCHEMBL30901148 | 0.93 | ADORA2A (0.54) | ADORA2AADORA2BADORA1PRKAG1PRKAA1 | |
| SCHEMBL2115365 | 0.90 | PRMT5 (0.46) | ADORA2AADORA2BPRMT5WDR77ADORA3 | |
| SCHEMBL9294052 | 0.87 | ADORA2A (0.49) | ADORA2AADORA2BADORA1PRKAG1PRKAA1 | |
| SCHEMBL9024698 | 0.86 | P2RY12 (0.49) | ADORA2AADORA2BPRMT5WDR77ADORA3 | |
| SCHEMBL2111739 | 0.86 | TYMP (0.48) | ADORA2AADORA2BADORA1PRKAG1PRKAA1 | |
| SCHEMBL9096320 | 0.85 | TYMP (0.56) | ADORA2AADORA2BADORA1PRKAG1PRKAA1 | |
| SCHEMBL5580213 | 0.85 | ADORA1 (0.57) | ADORA2BADORA1PRMT5WDR77ADORA3 | |
| SCHEMBL439195 | 0.84 | PRMT5 (0.45) | ADORA2AADORA2BPRMT5WDR77ADORA3 | |
| SCHEMBL7523809 | 0.84 | PRMT5 (0.45) | ADORA2AADORA2BPRMT5WDR77ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158770-B2 | Content dependent inhibitors of cytidine deaminases and uses thereof | UNIVERSITY OF ROCHESTER (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | DCTD, CDA, ADA | ADORA2A 608/4885ADORA2B 1327/4885ADORA1 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.